| Could you please repeat that? http://rc-lab.co.uk/about-us erythromycin without rx Strategas’s Mr. Verrone said given how strong the stock’s uptrend has been so far this year, he’s “not convinced” the stock is a short. That means he’s not willing to put on a new position betting the stock will decline. But he also doesn’t see a “buy-on-a-dip” opportunity until the stock falls to the 50-day moving average line. That line, which extends Monday to $139.22, according to FactSet, is widely viewed by technicians as short-term trend gauge.
|